

Table D.9 Pharmacokinetic data (continued)

| Medicine | Half-life (hours) | Clearance (Cl) ^a (mL/min/kg) | Fraction excreted unchanged (f _e) | Fraction unbound (f _u) | Oral bioavailability (F) | Comments |
|-----------------------------|--|--|--|--|-----------------------------|---|
| Azelastine | 22 azelastine, 56 desmethyl-azelastine | 7.6 | 0.13 | 0.12 azelastine, 0.03 desmethyl-azelastine | 0.2 | Desmethylazelastine is an active metabolite |
| Azithromycin | 70 | 9 | 0.06 | | | |
| Azlocillin | 1.5 | 3 | 0.6 | 0.7 | | |
| Aztreonam | 2 | 0.6 | 0.6 | 0.3 | | |
| Baclofen | 3 | | 0.8 | 0.7 | 0.7 | |
| Balsalazide | | | <0.01 | 0.01 | 0.01 | |
| Beclomethasone dipropionate | | 15 | | <0.01 | 0.1 | |
| Bendrofluzide | 4 | 4 | 0.3 | 0.05 | 0.9 | |
| Benzhexol | 9 | | <0.05 | 0.05 | | |
| Benzyloxyphenacillin | 0.5 | 10 | 0.75 | 0.4 | | |
| Betamethasone | 6 | 3 | 0.05 | 0.3 | 0.7 | |
| Bimatoprost | 0.75 | 25 | 0.67 | 0.1 | very low | |
| Bisoprolol | 10–12 | 3.7 | 0.5 | 0.65 | 0.85–0.90 | No active metabolites |
| Bleomycin | 3 | 1 | 0.4 | 0.99 | | |
| Bosentan | 6 | 1 | <0.03 | 0.02 | 0.4 | Clearance is non-linear and auto-inducible |
| Brinzolamide | 111 days | | >0.9 | 0.4 | | N-desethyl brinzolamide is an active metabolite |
| Bromazepam | 20 | 0.5 | 0.02 | 0.3 | | |
| Bromhexine | 6 | | <0.01 | | | |
| Bromocriptine | 7 | | <0.05 | 0.05 | <0.1 | |
| Budesonide | 2 | 15 | <0.01 | 0.1 | | Nasal bioavailability is 0.2 |
| Bumetanide | 1.5 | 3 | 0.5 | 0.05 | 0.8 | |
| Bupivacaine | 3 | 6 | 2 | 0.05 | | |
| Buprenorphine | 4 | 18 | <0.1 | 0.04 | | |
| Bupropion | 20 | 50 | <0.01 | 0.16 | | |
| Buspirone | 5 | 30 | <0.01 | 0.05 | | |
| Busulfan | 2.5 | 4.5 | <0.01 | | | |
| Cabergoline | 60–110 | | 0.02 | 0.6 | | |
| Calcitonin | 1 | 2 | <0.05 | | | |
| Calcitriol | 4.5 | | | | | Pharmacological half-life of 4 days |
| Candesartan cilexetil | 9* | 0.37* | 0.5* | 0.4* | | * Pro-drug of candesartan; parameters are for candesartan formed from the pro-drug |
| Capreomycin | 3 | | 0.5 | | | |
| Captopril | 1.5 | 13 | 0.4 | 0.7 | 0.7 | |
| Carbamazepine | 15 | 1.3 | <0.05 | 0.25 | >0.7 | Induces its own metabolism—values are for chronic therapy. Value for oral bioavailability is for conventional formulation (TDM) |
| Carbimazole | 0.85 | | 0.1 | >0.9 | | Rapidly hydrolysed to methimazole, which has a half-life of 3–5 hours |
| Carboplatin | 1.5 | 1.5 | 0.7 | | | |
| Carmustine | 0.3 | 60 | <0.01 | 0.2 | | |
| Cefaclor | 0.75 | 6 | 0.5 | 0.75 | | |
| Cefepime | 2 | 1.7 | 0.9 | 0.8 | | |
| Cefotaxime | 1.3 | 4 | 0.5 | 0.7 | | |
| Cefotetan | 3.5 | 0.4 | 0.6 | 0.1 | | |
| Cefoxitin | 0.7 | 4 | 0.8 | 0.3 | | |
| Cefpodoxime | 2 | 3 | 0.8 | 0.6 | | |
| Ceftazidime | 1.6 | 2 | 0.8 | 0.8 | | |
| Ceftriaxone | 7.3 | 0.3 | 0.5 | 0.2 | | |
| Celecoxib | 11 | 7 | 0.03 | 0.03 | | |
| Cephalexin | 1 | 4.3 | 0.9 | 0.85 | 0.9 | |

a. For some values in this table clearance has been calculated using the half-life